Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04023331 · ClinicalTrials.gov registry record · Phase 1
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
A Phase 1 study, sponsored by Clarity Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04023331 is a Phase 1 study that was terminated before completion, run by Clarity Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT04023331, a Phase 1 study, was terminated before completion, sponsored by Clarity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Interventions
- DRUG 67Cu-SARTATE
- DRUG 64Cu-SARTATE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04023331
The ClinicalTrials.gov registry entry for NCT04023331 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarity Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 67Cu-SARTATE is the first listed.
NCT04023331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04023331 about?
NCT04023331 is a clinical study titled "67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma". The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
What is the current status of trial NCT04023331?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-08-18. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT04023331?
The interventions under investigation include: 67Cu-SARTATE (DRUG), 64Cu-SARTATE (DRUG).
Who is sponsoring clinical trial NCT04023331?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.